ANGELALIGN TECHNOLOGY INC.
時代天使科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6699)

CONTINUING CONNECTED TRANSACTIONS

Non-exempt Continuing Connected Transactions – Continuing Connected Transactions under the 2027-2029 Clear Aligners Purchase and Sales Framework Agreement

Reference is made to the announcement of the Company dated October 24, 2023, in relation to, inter alia, the continuing connected transactions under the 2024-2026 Clear Aligners Purchase and Sales Framework Agreement entered into between Wuxi EA, a wholly-owned subsidiary of the Company, and CC Dental, a company controlled by CareCapital Group, the controlling Shareholder of the Company, which regulates the purchase and sales of the clear aligners and related products and services between CC Dental Group and the Group.

The 2024-2026 Clear Aligners Purchase and Sales Framework Agreement will expire on December 31, 2026. The Directors expect that the Group will continue to provide clear aligners and certain other products and services to CC Dental Group. In this connection, on June 25, 2026, CC Dental and Wuxi EA entered into the 2027-2029 Clear Aligners Purchase and Sales Framework Agreement for a term of three years, commencing from January 1, 2027 and ending on December 31, 2029.

The Annual Caps set for the purchases of the Group's products and services contemplated under the 2027-2029 Clear Aligners Purchase and Sales Framework Agreement for the years ending December 31, 2027, 2028 and 2029 are RMB275.0 million, RMB360.0 million and RMB465.0 million, respectively.

Partially-exempt Continuing Connected Transactions – Continuing Connected Transactions under the 2027-2029 Product Purchase Cooperation Framework Agreement

Reference is made to the announcement of the Company dated June 24, 2025, in relation to, inter alia, the continuing connected transactions under the Product Purchase Cooperation Framework Agreement entered into between Wuxi EA, a wholly-owned subsidiary of the Company, and Shanghai Kaihao, an associate (as defined under the Listing Rules) of Ms. Li, a substantial Shareholder of the Company, pursuant to which Wuxi EA shall purchase from Shanghai Kaihao certain raw materials for the production of clear aligners.

The Product Purchase Cooperation Framework Agreement will expire on December 31, 2026. The Directors expect that the Group will continue to procure certain raw materials for the production of clear aligners from Shanghai Kaihao. In this connection, on June 25, 2026, Shanghai Kaihao and Wuxi EA entered into the Product Purchase Cooperation Framework Agreement for a term of three years, commencing from January 1, 2027 and ending on December 31, 2029.

The Annual Caps set for the purchases of raw materials by the Group contemplated under the 2027-2029 Product Purchase Cooperation Framework Agreement for the years ending December 31, 2027, 2028 and 2029 are RMB72.0 million, RMB86.0 million and RMB95.0 million, respectively.

Listing Rules Implications

Continuing Connected Transactions under the 2027-2029 Clear Aligners Purchase and Sales Framework Agreement

CC Dental Group is controlled by CareCapital Group, the controlling Shareholder of the Company. Accordingly, CC Dental Group is a connected person of the Company under Rule 14A.07 of the Listing Rules and the transactions contemplated under the 2027-2029 Clear Aligners Purchase and Sales Framework Agreement constitute continuing connected transactions of the Company under Chapter 14A of the Listing Rules. As one or more of the applicable percentage ratios in respect of the Annual Caps are more than 5%, the related transactions under the 2027-2029 Clear Aligners Purchase and Sales Framework Agreement are subject to the reporting, annual review, announcement and independent shareholders' approval requirements under Chapter 14A of the Listing Rules.

A circular containing, among others, (i) further details of the 2027-2029 Clear Aligners Purchase and Sales Framework Agreement and the Annual Caps; (ii) a letter from Gram Capital, the Independent Financial Adviser, containing its advice to the Independent Board Committee and the Independent Shareholders; (iii) a letter from the Independent Board Committee to the Independent Shareholders, containing its advice to the Independent Shareholders; and (iv) a notice of the EGM, will be published on the website of the Stock Exchange (www.hkexnews.hk) and of the Company (www.angelalign.com) and will be dispatched by the Company to the Shareholders in due course.

Continuing Connected Transactions under the 2027-2029 Product Purchase Cooperation Framework Agreement

Shanghai Kaihao is owned by Ms. Li, a substantial Shareholder of the Company, as to 40%. As such, Shanghai Kaihao is a connected person of the Company under Rule 14A.07 of the Listing Rules, and the transactions contemplated under the Product Purchase Cooperation Framework Agreement constitute continuing connected transactions under Chapter 14A of the Listing Rules.

As one or more of the applicable percentage ratios in respect of the Annual Caps are more than 0.1% but lower than 5%, the transactions contemplated under the 2027-2029 Product Purchase Cooperation Framework Agreement are subject to the reporting, annual review and announcement requirements, but exempt from the independent Shareholders' approval requirement, under Chapter 14A of the Listing Rules.

A. THE 2027-2029 CLEAR ALIGNERS PURCHASE AND SALES FRAMEWORK AGREEMENT

The Board announces that on June 25, 2026, Wuxi EA, a wholly-owned subsidiary of the Company, entered into the 2027-2029 Clear Aligners Purchase and Sales Framework Agreement with CC Dental, a company controlled by CareCapital Group, the controlling shareholder of the Company, which regulates the purchase and sales of the clear aligners and related products and services between CC Dental Group and the Group.

The principal terms of the 2027-2029 Clear Aligners Purchase and Sales Framework Agreement are summarized as below:

Date: June 25, 2026

Parties: CC Dental and Wuxi EA

Major Terms:

Pursuant to the 2027-2029 Clear Aligners Purchase and Sales Framework Agreement, the Group agrees to grant to CC Dental Group rights to sell its clear aligners and certain other products and services such as MOOELI, oral consumer goods and intraoral scanners in regions in China as agreed between CC Dental Group and the Group from time to time, and CC Dental Group agrees to purchase from the Group and sell to third parties the Group's clear aligners and certain other products and services accordingly. The 2027-2029 Clear Aligners Purchase and Sales Framework Agreement has a term of three years, commencing from January 1, 2027 to December 31, 2029.

Pricing Policy:

Fees charged by the Group for purchases of its clear aligners and other products and services shall be primarily determined based on the general guide on sales price of such goods as provided by the Group from time to time to the distributors (including independent distributors), with certain adjustment determined from time to time by the parties on an arm's length basis with reference to the sales volume and historical performance. The Group generally determines, on an annual basis, the sales price with the CC Dental Group based on arm's length negotiations after taking into account of primarily (i) the general guide sales price the Group provided to its purchasers (including independent purchasers) for the corresponding year; (ii) the total sales volume the counterparty agreed to purchase from the Group; (iii) the length of business relationship with such respective purchasers; and (iv) the industry position and sales capacity of such respective purchasers. The Group generally determines, on an annual basis, the general guide sales price of clear aligners and other products and services based on the estimated gross profit of its products and services for such year and the estimated market demand in such year. The Group generally settled payment directly with CC Dental Group for the goods purchase price and CC Dental Group generally paid the Group on a monthly basis. Specific price and payment will be made according to the respective contracts as further entered into between CC Dental Group and the Group under the 2027-2029 Clear Aligners Purchase and Sales Framework Agreement, which shall be in line with the pricing policy and the general guide sales price the Group provides to a similar independent distributor.

THE HISTORICAL TRANSACTION AMOUNTS AND EXPECTED ANNUAL CAPS

Historical Transaction Amounts

The historical transaction amounts for the purchases of the Group's clear aligners, intraoral scanners and other products and services relating to the 2024-2026 Clear Aligners Purchase and Sales Framework Agreement for the two years ended December 31, 2025 and the period from January 1, 2026 to May 31, 2026 are as follows:

	For the year ended December 31, 2024	For the year ended December 31, 2025	For the period from January 1, 2026 to May 31, 2026 *(unaudited)*
Historical transaction amounts	RMB106.0 million	RMB140.5 million	RMB46.2 million

Expected Annual Caps of Clear Aligners

The Annual Caps set for the purchases of the Group's products and services contemplated under the 2027-2029 Clear Aligners Purchase and Sales Framework Agreement are as follows:

	For the year ending December 31, 2027	For the year ending December 31, 2028	For the year ending December 31, 2029
The Annual Caps	RMB275.0 million	RMB360.0 million	RMB465.0 million

In determining the Annual Caps, the Directors have considered, among others, the following factors: (i) the historical transaction amount and its growth rate in previous years noting in particular that (a) the historical amount under the 2024-2026 Clear Aligners Purchase and Sales Framework Agreement increased by approximately 33% from 2024 to 2025, and further increased by approximately 53% for the five months ended May 31, 2026 as compared to the corresponding period in 2025, demonstrating strong growth momentum; (ii) the estimated growth of the transaction amount of the Group's products and services under the 2027-2029 Clear Aligners Purchase and Sales Framework Agreement (with an estimated year-to-year growth of approximately 30% for each of the three years ending December 31, 2029), which is in line with the Group's overall business expansion and expected revenue growth, underpinned by the Group's continued deepening of its strategic presence in Chinese mainland market, particularly in lower-tier cities, through the enhancement of its product portfolio, strengthening of clinical support capabilities and the ongoing expansion of application scenarios for clear aligner solutions; (iii) the anticipated increase in transaction amount brought by the potential acquisition of the Group's pre-existing distributors by CC Dental Group in 2027-2029; and (iv) the Group's strategy to consolidate its market share leadership in the Chinese mainland market, especially in lower-tier cities through distributors (including CC Dental and independent distributors); and (v) a buffer of 8% for each of the three years ending December 31, 2029, the incorporation of which is common among continuing connected transactions of other companies listed on the Stock Exchange.

REASONS FOR AND BENEFITS OF ENTERING INTO THE CONTINUING CONNECTED TRANSACTIONS UNDER THE 2027-2029 CLEAR ALIGNERS PURCHASE AND SALES FRAMEWORK AGREEMENT

CC Dental Group is one of the major national distributors in China's dental industry and is expanding rapidly in the dental industry. Given the large sales network of CC Dental Group in China and the competitive advantages of various distributors under CC Dental Group, the Group benefits from the business cooperation with CC Dental Group in CC Dental Group's network of sales of its products and related services as well as expansion and promotion of its products and brands among the hospitals and dental clinics in China, which shall in turn further enhance the Group's competitiveness. The Directors are not aware of any disadvantages of the transactions under the 2027-2029 Clear Aligners Purchase and Sales Framework Agreement for the Group.

The Directors (including the independent non-executive Directors) are of the view that the continuing connected transactions under the 2027-2029 Clear Aligners Purchase and Sales Framework Agreement are (i) in the ordinary and usual course of the Group's business; (ii) on normal commercial terms or better; and (iii) fair and reasonable and in the interests of the Group and the Shareholders as a whole.

Except for Mr. FENG Dai, Mr. HUANG Kun and Mr. HU Jiezhang, who hold positions in CareCapital Group, the controlling Shareholder of the Company and CC Dental Group, had abstained from voting on the resolutions in respect of the 2027-2029 Clear Aligners Purchase and Sales Framework Agreement at the Board meeting, none of the other Directors has material interests in the aforesaid transaction or is required to abstain from voting on such resolutions.

INTERNAL CONTROL MEASURES

The Company has adopted the following internal control and corporate governance measures in ensuring the selling price of the transactions contemplated under the 2027-2029 Clear Aligners Purchase and Sales Framework Agreement complies with the pricing policy:

(1) the Company has adopted and implemented a management system on connected transactions and the Board and various internal departments of the Company (the "Relevant Departments", including several business departments, financial department, internal control department and board secretary department of the Company) are responsible for the control and daily management in respect of the continuing connected transactions;

(2) the Board and the Relevant Departments are jointly responsible for evaluating, on a monthly basis, the terms of the continuing connected transactions, in particular, the fairness of the pricing policies, payment terms and annual caps (if applicable) under each transaction with reference to market benchmark, including the sales prices of at least three comparable peer companies, and the price the Group offers to independent third party customers;

(3) the Board and the Relevant Departments are regularly monitoring, on a monthly basis, the connected transactions and the management of the Company (including but not limited to Executive Directors, chief strategy officer and head of the Relevant Departments) will regularly review the pricing policies to ensure the connected transactions to be performed in accordance with the relevant agreements and within the approved annual caps. In addition, where the transaction amount for the relevant year reaches 70% of the applicable annual cap, the Relevant Departments shall promptly report the same to the Board;

(4) the Company has adopted and implemented a distributor management policy on managing all its distributors, which governs the entire process of engaging and changing distributors and relevant arrangements, pursuant to which, all the distributors are subject to the same requirements such as qualification, compliance, settlement, performance review process. The Company has also adopted internal policy managing the sales prices with the distributors (including distributors who are connected persons of the Company), which requires the Company to apply the same pricing policy and guide price to all its distributors and to determine its general sales guide on annual basis. The Relevant Departments are primarily responsible for determining the sales prices with all the distributors and monitoring the implementation of the distributor management and pricing policy;

(5) the Company has engaged external independent auditor which will, and the independent non-executive Directors also will, conduct annual review on the continuing connected transactions to ensure that the transactions contemplated thereunder have been conducted pursuant to the requirements of the Listing Rules and have fulfilled the relevant disclosure requirements; and

(6) the Company will continue to comply with the relevant requirements under Chapter 14A of the Listing Rules for the continuing connected transactions.

INFORMATION ABOUT THE PARTIES

The Group

The Company was incorporated in the Cayman Islands on November 29, 2018, as an exempted company with limited liability under the Cayman Companies Act. The Company is an investment holding company. The Group is one of the global leaders in clear aligner innovation, combining over two decades of research, digital advancement, and clinical expertise.

CC Dental Group

CC Dental Group is established in the PRC and is wholly-controlled by CareCapital Group, the controlling Shareholder of the Company. CC Dental Group is one of the major distribution service providers in China's dental industry, and principally engages in distributing and selling full range of dental products including, among others, dental devices, equipment and consumable. CC Dental Group is committed to serving dental institutions and professionals across the country with products and services from dental devices and equipment, digital solutions, dental clinic management software to comprehensive specialized services.

LISTING RULES IMPLICATIONS

CC Dental Group is controlled by CareCapital Group, which is the controlling Shareholder of the Company. As such, CC Dental Group is a connected person of the Company under Rule 14A.07 of the Listing Rules, and transactions between CC Dental Group and the Group constitute continuing connected transactions under Chapter 14A of the Listing Rules.

As one or more of the applicable percentage ratios in respect of the Annual Caps are more than 5% and no exemption is available under the Listing Rules, the related transactions under the 2027-2029 Clear Aligners Purchase and Sales Framework Agreement are subject to the reporting, annual review, announcement and independent shareholders' approval requirements under Chapter 14A of the Listing Rules.

As at the date of this announcement, CareCapital Group and Mr. FENG Dai, the ultimate controlling person of CareCapital Group, are interested in 87,168,400 Shares, representing approximately 51.01% of the issued share capital of the Company by virtue of their control over CareCapital Orthotech Limited, and such interest represents a deemed interest arising from the voting rights attached to the relevant Shares; Mr. HUANG Kun, who serves as a partner of CareCapital Group, through Noble Affluent Limited, in aggregate controlled 217,200 Shares, representing approximately 0.13% of the issued share capital of the Company. Accordingly, CareCapital Orthotech Limited and Noble Affluent Limited are required to abstain from voting at the EGM in respect of the resolutions on the 2027-2029 Clear Aligners Purchase and Sales Framework Agreement as a result of having material interest therein. To the best of the Directors' knowledge, information and belief after having made all reasonable enquiries, save as disclosed in this announcement, no other Shareholder is required to abstain from voting at the EGM.

The Company has established the Independent Board Committee to advise the Independent Shareholders in respect of the 2027-2029 Clear Aligners Purchase and Sales Framework Agreement, which comprises all the three independent non-executive Directors, who have no material interest in the transactions contemplated under the 2027-2029 Clear Aligner Purchases and Sales Framework Agreement. The Independent Board Committee will advise the Independent Shareholders on voting at the EGM on the resolutions in respect of the 2027-2029 Clear Aligner Purchases and Sales Framework Agreement, after taking into account the recommendations of the Independent Financial Adviser.

In this connection, the Company has appointed Gram Capital as the Independent Financial Adviser to advise the Independent Board Committee and the Independent Shareholders in relation to the 2027-2029 Clear Aligner Purchases and Sales Framework Agreement.

The Company will disclose the information in relation to the 2027-2029 Clear Aligner Purchases and Sales Framework Agreement in its subsequent published annual report and accounts in accordance with Rule 14A.49 of the Listing Rules.

A circular containing, among others, (i) further details of the 2027-2029 Clear Aligners Purchase and Sales Framework Agreement and the Annual Caps; (ii) a letter from Gram Capital, the Independent Financial Adviser, containing its advice to the Independent Board Committee and the Independent Shareholders; (iii) a letter from the Independent Board Committee to the Independent Shareholders, containing its advice to the Independent Shareholders; and (iv) a notice of the EGM, will be published on the website of the Stock Exchange (www.hkexnews.hk) and of the Company (www.angelalign.com) and will be dispatched by the Company to the Shareholders in due course.

B. 2027-2029 PRODUCT PURCHASE COOPERATION FRAMEWORK AGREEMENT

The Board announces that on June 25, 2026, Wuxi EA, a wholly-owned subsidiary of the Company, entered into the 2027-2029 Product Purchase Cooperation Framework Agreement with Shanghai Kaihao, an associate (as defined under the Listing Rules) of Ms. Li, a substantial Shareholder, pursuant to which Wuxi EA shall purchase from Shanghai Kaihao certain raw materials for the production of clear aligners.

The principal terms of the 2027-2029 Product Purchase Cooperation Framework Agreement are summarized as follows:

Date: June 25, 2026

Parties: Shanghai Kaihao and Wuxi EA

Major Terms:

Pursuant to the 2027-2029 Product Purchase Cooperation Framework Agreement, Wuxi EA will purchase certain raw materials produced by Shanghai Kaihao for the production of clear aligners, in accordance with the written contracts as shall be further entered into between Shanghai Kaihao and Wuxi EA from time to time.

The Product Purchase Cooperation Framework Agreement has a term commencing on January 1, 2027 to December 31, 2029.

Pricing Policy:

The purchase price of the raw materials shall be determined through fair negotiations on an arm's length basis by Wuxi EA and Shanghai Kaihao with reference to the prevailing market competition conditions comprehensively. In particular, such price shall be based on the market guideline price given to other third party buyers by Shanghai Kaihao and shall not be less favorable than the prices or conditions offered by Shanghai Kaihao to other third party buyers. Shanghai Kaihao is entitled to adjust the purchase price according to the market conditions, if there is adjustment, Shanghai Kaihao and Wuxi EA shall negotiate to reach consensus. The Group shall only purchase raw materials from Shanghai Kaihao at comparable market prices not higher than those offered to such other third party buyers. Comparable market prices refer to the prices arrived at with reference to those charged or quoted by at least two independent third parties offering the same or similar raw materials with a comparable scale of raw material sales in areas where such materials were then sold under normal trading conditions.

The specific purchase price and settlement arrangement will be subject to the relevant terms of the respective contracts as further entered into between Wuxi EA and Shanghai Kaihao under the 2027-2029 Product Purchase Cooperation Framework Agreement, which shall generally be in line with the business practice between Shanghai Kaihao and its other third party buyers.

THE HISTORICAL TRANSACTION AMOUNTS AND EXPECTED ANNUAL CAPS

Historical Transaction Amounts

The historical transaction amounts for the purchases of raw materials for the production of clear aligners by the Group from Shanghai Kaihao relating to the Product Purchase Cooperation Framework Agreement for the six months ended December 31, 2025 and the period from January 1, 2026 to May 31, 2026 are as follows:

	For the six months ended December 31, 2025	**For the period from January 1, 2026 to May 31, 2026** *(unaudited)*
Historical transaction amounts	RMB24.6 million	RMB21.2 million

Expected Annual Caps of Shanghai Kaihao

The Annual Caps set for the purchases of raw materials for the production of clear aligners by the Group from Shanghai Kaihao as contemplated under the 2027-2029 Product Purchase Cooperation Framework Agreement are as follows:

	For the year ending December 31, 2027	For the year ending December 31, 2028	For the year ending December 31, 2029
The Annual Caps	RMB72.0 million	RMB86.0 million	RMB95.0 million

In determining the Annual Caps, the Directors have considered the following factors: (i) the purchasing strategy of raw materials for the production of clear aligners of the Group in the following three years from 2027 to 2029; and (ii) the estimated raw material demands for the production of clear aligners in the following three years from 2027 to 2029.

REASONS FOR AND BENEFITS OF ENTERING INTO THE CONTINUING CONNECTED TRANSACTIONS UNDER THE PRODUCT PURCHASE COOPERATION FRAMEWORK AGREEMENT

Shanghai Kaihao is a raw materials supplier in the clear aligner industry. Given the expanding demands for the raw materials in the clear aligner production process due to the growth in the Group's clear aligner business in Chinese mainland and global markets, the Directors believe that it is crucial for the Group to procure the raw materials from reliable suppliers and to form a long-term cooperation with such suppliers. As such, the Group intended to strengthen its business cooperation with Shanghai Kaihao.

The Directors (including the independent non-executive Directors) are of the view that the continuing connected transactions contemplated under the 2027-2029 Product Purchase Cooperation Framework Agreement are (i) in the ordinary and usual course of the Group's business; (ii) on normal commercial terms or better; and (iii) fair and reasonable and in the interests of the Group and the Shareholders as a whole.

None of the Directors has a material interest in the transactions contemplated under the 2027-2029 Product Purchase Cooperation Framework Agreement and none of the Directors is required to abstain from voting on such resolutions in respect of the 2027-2029 Product Purchase Cooperation Framework Agreement and the transactions contemplated thereunder at the relevant Board meeting.

INTERNAL CONTROL MEASURES

The Company has adopted the following internal control and corporate governance measures in ensuring the purchase price of the transactions contemplated under the 2027-2029 Product Purchase Cooperation Framework Agreement complies with the pricing policy:

(1) the Company has adopted and implemented a management system on connected transactions and the Board and various internal departments of the Company (the "Relevant Departments", including several business departments, financial department, internal control department and board secretary department of the Company) are responsible for the control and daily management in respect of the continuing connected transactions;

(2) the Board and the Relevant Departments are jointly responsible for evaluating the terms of the continuing connected transactions, in particular, the fairness of the pricing policies, payment terms and annual caps (if applicable) under each transaction with reference to market benchmark and the price the Group offers to independent third party suppliers;

(3) the Board and the Relevant Departments are regularly monitoring the connected transactions and the management of the Company (including but not limited to Executive Directors, chief strategy officer and head of the Relevant Departments) will regularly review the pricing policies to ensure the connected transactions to be performed in accordance with the relevant agreements and within the approved annual caps;

(4) the Company has engaged external independent auditor which will, and the independent non-executive Directors also will, conduct annual review on the continuing connected transactions to ensure that the transactions contemplated thereunder have been conducted pursuant to the requirements of the Listing Rules and have fulfilled the relevant disclosure requirements; and

(5) the Company will continue to comply with the relevant requirements under Chapter 14A of the Listing Rules for the continuing connected transactions.

INFORMATION ON THE PARTIES TO THE PRODUCT PURCHASE COOPERATION FRAMEWORK AGREEMENT

The Group

The Company was incorporated in the Cayman Islands on November 29, 2018, as an exempted company with limited liability under the Cayman Companies Act. The Company is an investment holding company. The Group is one of the global leaders in clear aligner innovation, combining over two decades of research, digital advancement, and clinical expertise.

Shanghai Kaihao

Shanghai Kaihao is established in the PRC and is owned as to 59.0% by Shanghai Kuohong Information Technology Co., Ltd. (上海闊鴻信息科技有限公司), which together with its ultimate beneficial owner, are independent third parties of the Company, and as to 40.0% by Ms. Li, a substantial Shareholder of the Company. Shanghai Kaihao is a raw materials supplier in the clear aligner industry.

LISTING RULES IMPLICATIONS

Shanghai Kaihao is owned by Ms. Li, a substantial Shareholder of the Company, as to 40%. As such, Shanghai Kaihao is a connected person of the Company under Rule 14A.07 of the Listing Rules, and the transactions contemplated under the 2027-2029 Product Purchase Cooperation Framework Agreement constitute continuing connected transactions under Chapter 14A of the Listing Rules.

As one or more of the applicable percentage ratios in respect of the Annual Caps are more than 0.1% but lower than 5%, the transactions contemplated under the 2027-2029 Product Purchase Cooperation Framework Agreement are subject to the reporting, annual review and announcement requirements, but exempt from the independent Shareholders' approval requirement, under Chapter 14A of the Listing Rules.

The Company will disclose the information in relation to the 2027-2029 Product Purchase Cooperation Framework Agreement in its subsequent published annual reports and accounts in accordance with Rule 14A.49 of the Listing Rules.

DEFINITIONS

"2024-2026 Clear Aligners Purchase and Sales Framework Agreement"	the clear aligners purchase and sales framework agreement entered into between Wuxi EA and CC Dental on October 24, 2023
"2027-2029 Clear Aligners Purchase and Sales Framework Agreement"	the clear aligners purchase and sales framework agreement entered into between Wuxi EA and CC Dental on June 25, 2026
"2027-2029 Product Purchase Cooperation Framework Agreement"	the product purchase cooperation framework agreement entered into between Wuxi EA and Shanghai Kaihao on June 25, 2026
"Annual Caps of Clear Aligners"	The annual caps of the total revenues from CC Dental Group to the Group for purchases of the Group's products and services under the 2027-2029 Clear Aligners Purchase and Sales Framework Agreement for the years ending December 31, 2027, 2028 and 2029
"Annual Caps of Shanghai Kaihao"	The annual caps of the total revenues from the Group to Shanghai Kaihao for purchases of certain raw materials for the production of clear aligners under the 2027-2029 Product Purchase Cooperation Framework Agreement for the years ending December 31, 2027, 2028 and 2029
"associate(s)"	has the meaning ascribed thereto under the Listing Rules
"Board"	the board of directors of the Company
"CareCapital Group"	Mr. FENG Dai and the entities controlled by him directly or indirectly for holding interests in the Company under the trade name of CareCapital
"CC Dental"	Shanghai CareCapital Dental Devices Co., Ltd. (上海松佰牙科器械有限公司)
"CC Dental Group"	CC Dental and its subsidiaries
"Company"	Angelalign Technology Inc. (時代天使科技有限公司), an exempted company incorporated under the laws of Cayman Islands with limited liability on November 29, 2018, the shares of which are listed on the Main Board of the Stock Exchange
"connected person"	has the meaning ascribed thereto under the Listing Rules
"controlling shareholder"	has the meaning ascribed thereto under the Listing Rules
"Director(s)"	the director(s) of the Company

"EGM"	the extraordinary general meeting of the Company to be held on or around July 17, 2026, which will be further notified by the Company in due course
"Group"	the Company and its subsidiaries
"Hong Kong"	the Hong Kong Special Administrative Region of the PRC
"Independent Board Committee"	an independent committee of the Board comprising all the independent non-executive Directors as established by the Board pursuant to the Listing Rules to advise the Independent Shareholders in respect of terms of the 2027-2029 Clear Aligners Purchase and Sales Framework Agreement and transactions contemplated thereunder
"Independent Financial Adviser" or "Gram Capital"	Gram Capital Limited, a licensed corporation to carry out Type 6 (advising on corporate finance) regulated activity under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), being the independent financial adviser to the Independent Board Committee and the Independent Shareholders in respect of the 2027-2029 Clear Aligners Purchase and Sales Framework Agreement and the transactions contemplated thereunder (including the Annual Caps)
"Independent Shareholders"	the Shareholders other than CareCapital Group and its associates
"Listing Rules"	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended or supplemented from time to time
"Ms. Li"	Ms. LI Huamin, a substantial Shareholder
"PRC" or "China"	the People's Republic of China excluding Hong Kong, the Macau Special Administrative Region of the PRC and Taiwan solely for the purpose of this announcement
"Product Purchase Cooperation Framework Agreement "	the product purchase cooperation framework agreement entered into between Wuxi EA and Shanghai Kaihao on June 24, 2025
"RMB"	renminbi, the lawful currency of the PRC
"Shanghai Kaihao"	Shanghai Kaihao Technology Co., Ltd. (上海愷皓科技有限公司), a company incorporated under the laws of the PRC with limited liability and owned as to 59.0% by Shanghai Kuohong Information Technology Co., Ltd. (上海闊鴻信息科技有限公司) and 40.0% by Ms. Li Huamin

"Share(s)"	ordinary share(s) in the share capital of the Company of US$0.0001 each
"Shareholder(s)"	holder(s) of the Shares
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"subsidiary(ies)"	has the meaning ascribed thereto under the Listing Rules
"substantial shareholder"	has the meaning ascribed thereto under the Listing Rules
"Wuxi EA"	Wuxi EA Medical Instruments Technologies Limited (無錫時代天使醫療器械科技有限公司), a company incorporated under the laws of the PRC with limited liability and a wholly-owned subsidiary of the Company

By Order of the Board
Angelalign Technology Inc.
Mr. FENG Dai
Chairman

Hong Kong, June 25, 2026

As at the date of this announcement, the Board comprises Mr. FENG Dai, Mr. HU Jiezhang, Mr. HUANG Kun and Ms. DONG Li as executive Directors; Mr. HAN Xiaojing, Mr. SHI Zi and Mr. ZHOU Hao as independent non-executive Directors.